Dudediligence.

aTyr Pharma, Inc

ATYRNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24$0.00Mar ’25$0.00Jun ’25$190,000Sep ’25$0.00Dec ’25
Net income, by quarter
−$17.3MSep ’24−$15.0MDec ’24−$14.9MMar ’25−$19.5MJun ’25−$25.7MSep ’25−$14.0MDec ’25−$10.8MMar ’26−$10.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$10.4M$353,000$235,000$190,000
Operating income−$34.0M−$46.4M−$54.9M−$67.9M−$77.6M
Net income−$33.8M−$45.3M−$50.4M−$64.0M−$74.1M
Operating cash flow−$33.1M−$41.9M−$33.2M−$69.1M−$62.0M
Free cash flow−$33.3M−$43.5M−$37.4M−$69.2M−$62.1M
Cash$2.3M$10.0M$22.5M$11.1M$10.7M
Shares outstanding27.8M29.5M63.3M84.0M98.0M